Tibotec expands
access to experimental anti-HIV drug

Tibotec Therapeutics announced it has expanded access to TMC114, an experimental anti-HIV drug. The program will provide a treatment option for HIV-positive patients in need of the drug, the company said. TMC114 is an experimental protease inhibitor that has shown some success in early tests of treating strains of the virus that are resistant to other protease drugs. For more information about TMC114 or the expanded access program visit www.tibotec.com. (AP, with additional reporting by Advocate.com)